Founded in 2020, AHEAD Medicine is redefining blood cancer diagnostics with AI-powered automation! Led by CEO Dr. Yu-Fen Wang, along with NTU Cancer Center’s Dr. Po-Sheng Ke and NTHU’s Prof. Chi-Chun Lee, the team tackles the global shortage of flow cytometry experts with a game-changing AI solution.
What’s the breakthrough?

• Cuts testing time from 30 minutes to just 7 seconds 
• Backed by top industry & academic partners 
• On track for FDA approval by 2027 
• Secured investment from Berkeley SkyDeck 

This AI-driven innovation isn’t just a tech milestone—it’s rewriting the textbooks of blood cancer diagnostics! 
Read more: http://bit.ly/v116company
Follow #Globalbio for the latest in AI, biotech, & medtech! 
#AIHealthcare #BloodCancer #PrecisionMedicine #FlowCytometry #MedicalAI #AHEADMedicine #BiotechInnovation #Globalbio #FDAApproval #SkyDeck #MedicalBreakthrough